Literature DB >> 2159932

Serum and v-src increase the level of a CCAAT-binding factor required for transcription from a retroviral long terminal repeat.

A Dutta1, M Y Stoeckle, H Hanafusa.   

Abstract

Transcription from the long terminal repeat (LTR) of Rous sarcoma virus (RSV) in rat 3Y1 fibroblasts was dependent on the presence of serum. Within 1 hr after addition of serum to a serum-deprived culture, there was a fivefold increase in the level of transcripts initiated at the LTR. This stimulation did not require synthesis of new proteins. The induction of transcription by serum was mostly dependent on two CCAAT boxes in the LTR. Within 1 hr after addition of serum, there was also an increase in the level of a nuclear protein that bound to the two CCAAT boxes, even in the presence of cycloheximide. This serum-induced CCAAT factor also bound CCAAT sequences from other promoters, for example, those of human heat shock protein 70, human c-Ha-ras, and human histone 1, but not to the adenovirus origin of replication or the SV40 enhancer core sequence, suggesting that it was related to CP1 or CP2. Expression from the RSV LTR was not dependent on serum in v-src-transformed cells. Using temperature-sensitive v-src, it was shown that the tyrosine kinase activity of the oncogene increased the amount of CCAAT factor that was present in the nucleus. These findings demonstrate that a basal transcription factor, the CCAAT-binding factor, could be a second messenger for transducing a primary signal from serum to the cellular transcriptional apparatus. This also suggests a pathway by which a tyrosine kinase oncogene could influence the transcription of several genes in the nucleus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2159932     DOI: 10.1101/gad.4.2.243

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  19 in total

1.  Negative autoregulation of the neu gene is mediated by a novel enhancer.

Authors:  X Y Zhao; M C Hung
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

2.  CArG, CCAAT, and CCAAT-like protein binding sites in avian retrovirus long terminal repeat enhancers.

Authors:  K R Zachow; K F Conklin
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

3.  Transcriptional activation of the CEF-4/9E3 cytokine gene by pp60v-src.

Authors:  M Dehbi; A Mbiguino; M Beauchemin; G Chatelain; P A Bédard
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

4.  Transcription of muscle-specific genes is repressed by reactivation of pp60v-src in postmitotic quail myotubes.

Authors:  G Falcone; S Alemà; F Tatò
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

5.  Initiation of transcription from the minute virus of mice P4 promoter is stimulated in rat cells expressing a c-Ha-ras oncogene.

Authors:  P Spegelaere; B van Hille; N Spruyt; S Faisst; J J Cornelis; J Rommelaere
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

6.  Compilation of vertebrate-encoded transcription factors.

Authors:  S Faisst; S Meyer
Journal:  Nucleic Acids Res       Date:  1992-01-11       Impact factor: 16.971

7.  The v-src inducible gene 9E3/pCEF4 is regulated by both its promoter upstream sequence and its 3' untranslated region.

Authors:  G A Blobel; H Hanafusa
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

8.  Chicken YB-2, a Y-box protein, is a potent activator of Rous sarcoma virus long terminal repeat-driven transcription in avian fibroblasts.

Authors:  S K Swamynathan; A Nambiar; R V Guntaka
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

9.  Ras-independent transformation by v-Src.

Authors:  D T Aftab; J Kwan; G S Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

10.  Transcriptional down regulation of the nov proto-oncogene in fibroblasts transformed by p60v-src.

Authors:  G Scholz; C Martinerie; B Perbal; H Hanafusa
Journal:  Mol Cell Biol       Date:  1996-02       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.